Forge Biologics has something rare for most early-stage biotech startups: revenue from customers. Now it has $40 million to expand its model, which places contract manufacturing alongside the development of its own gene therapies, the most advanced of which is being readied for tests in humans.
From operations in Columbus, OH, Forge makes gene therapies for other companies. The company was initially conceived solely as a contract manufacturer, CEO Tim Miller (pictured above) told Xconomy. The explosion of gene therapy research is leading to growing demand for manufacturing capabilities—much more than the industry is forecast to supply in coming years. Miller says Forge will do its part to help address those needs.
Read In Full: